Fresenius Medical Care stock trades close to analyst fair value as investors weigh guidance and sector peers

Fresenius Medical Care AG & Co. KGaA (ISIN DE0005785802) stock most recently closed at $23.75 on the New York Stock Exchange on August 14, 2026, giving investors a clear reference level for assessing current valuation and earnings expectations. Per a detailed stock overview reported by a MarketBeat competitors page, this closing price was also indicated in extended trading on the same date, underscoring a stable finish across regular and after-hours sessions.

Recent price levels and analyst targets

The same MarketBeat-derived overview cited in the report shows that Fresenius Medical Care shares traded at a current price reference of $23.54 as of August 17, 2026, at 3:58 p.m. Eastern, reflecting a modest intraday decline of 0.97 percent compared with the prior close of $23.77. According to an analyst forecast compilation, the average 12-month price target currently stands at $23.57, which represents an implied upside of 0.11 percent from the $23.54 quote as of August 17, 2026.

The same analyst overview notes a high target forecast of $25.80 and a low forecast of $19.90, suggesting that the spread between bullish and more cautious scenarios spans $5.90 per share based on current views. With the average target of $23.57 only $0.03 above the recent price reference of $23.54, the consensus implies that Fresenius Medical Care stock is trading close to what analysts consider its fair value, leaving limited room for multiple expansion without further earnings or cash flow surprises.

Valuation signals from US and European coverage

In addition to the MarketBeat-based consensus, another recent valuation-focused article highlights that Fresenius-associated American Depositary Receipts trade materially below a reported fair value estimate of $38 per ADR, implying a significant discount to that specific intrinsic value framework for the broader Fresenius group. While this fair value reference pertains to the parent company context rather than Fresenius Medical Care alone, it reinforces that parts of the group are seen as undervalued on certain fundamental metrics compared with long-term estimates of normalized earnings power.

At the same time, a separate corporate-focused piece on Fresenius SE & Co. KGaA stock indicates that the parent company shares changed hands at EUR 46.68 on August 18, 2026, with the price down 1.47 percent on the day and modestly below a consensus target of EUR 55.86. This context suggests that both the parent and Fresenius Medical Care entities are trading at levels below at least some fair value estimates, yet the much tighter gap between the Fresenius Medical Care ADR price of $23.54 and its $23.57 analyst target underscores that the dialysis specialist faces less upside in the near term unless new catalysts emerge.

Consensus focus on execution and margins

The MarketBeat-based forecast overview indicates that the average analyst price target for Fresenius Medical Care of $23.57 reflects a cautious stance on the company’s medium-term earnings trajectory, with limited implied upside from the current ADR price level. With the high forecast of $25.80 only $2.26 above the $23.54 reference price, and the low forecast of $19.90 just $3.64 below, the distribution suggests that analysts anticipate modest swings in either direction rather than extreme volatility, provided that operational performance in dialysis services and related products remains broadly on track.

For investors, the narrow 0.11 percent gap between the current price and the average target means that fundamentals such as revenue growth, operating margins, and free cash flow generation in upcoming quarters will be crucial for driving any re-rating. If Fresenius Medical Care can deliver sustained improvements in profitability or demonstrate stronger cash returns to shareholders, the stock could move closer to the upper end of the $19.90 to $25.80 target range, whereas underperformance relative to expectations could push the shares back toward the lower bound.

Peer and sector positioning

The competitors overview compiled by MarketBeat also situates Fresenius Medical Care alongside other health care equipment and services companies, allowing investors to compare valuation metrics like price-to-earnings ratios, dividend yields, and share price performance over the past year. With the FMS ticker quoted at $23.54 as of August 17, 2026, the small discount to the $23.57 consensus target contrasts with some peers that trade at larger premiums or discounts to their respective analyst fair values, indicating that the market may already incorporate much of the available information on Fresenius Medical Care’s risk and return profile.

Against this backdrop, sector-level commentary pointing to the Fresenius group’s ADRs trading well below a separate $38 fair value estimate underscores that perception of undervaluation is more pronounced at the parent-company level than at the Fresenius Medical Care subsidiary. Investors who focus on the dialysis business specifically therefore need to weigh the relatively fully valued ADR price against operational improvements, cost control measures, and potential regulatory or reimbursement changes in key markets, which could affect future earnings trajectories.

Representative product focus: dialysis care solutions

As a global provider of dialysis-related services, Fresenius Medical Care centers much of its business model on comprehensive dialysis care solutions for patients with chronic kidney failure. These offerings typically span in-center hemodialysis treatments, home dialysis options, and related supplies and equipment that support long-term therapy, enabling patients to receive regular blood purification and fluid balance management in line with clinical guidelines.

Beyond treatment delivery, Fresenius Medical Care also focuses on integrating patient care pathways, including coordinating with nephrologists, hospitals, and other health care providers to improve outcomes and quality of life. By combining clinical expertise, standardized processes, and investment in technology, the company aims to enhance survival rates and reduce complications for dialysis patients, while simultaneously managing costs for payers and health systems across multiple regions.

Fresenius Medical Care stock: key reference price

As of the most recent completed trading session on August 14, 2026, Fresenius Medical Care stock closed at $23.75 on the New York Stock Exchange, providing a concrete benchmark for tracking subsequent price moves and evaluating valuation metrics such as dividend yield and price-to-earnings ratios. With the later MarketBeat-based reference price of $23.54 as of August 17, 2026, indicating a 0.88 percent decline from the August 14, 2026, close, investors can observe that the stock has stayed within a tight range while consensus targets signal minimal implied upside at current levels.

Fact box

Company: Fresenius Medical Care AG & Co. KGaA
ISIN: DE0005785802
Ticker: FMS
Exchange: New York Stock Exchange
Price (as of August 14, 2026, 3:59 p.m. ET): $23.75 USD
Sector / Industry: Health care equipment and services